LabCorp v. Ravgen (23-1342): Federal Circuit Affirms Genetic Disorder Detection Patent
Laboratory Corporation of America Holdings challenged the validity of Ravgen’s US7332277B2, a patent covering methods for detecting genetic disorders. After a 731-day appeal before the Federal Circuit, the court issued a single-word affirmance — leaving Ravgen’s patent fully intact and LabCorp’s invalidity arguments extinguished at the appellate level.
Federal Circuit shuts down LabCorp’s patent invalidity bid over Ravgen diagnostics IP
Laboratory Corporation of America Holdings — one of the largest clinical laboratory networks in the United States — filed this appeal on January 6, 2023, seeking to overturn a ruling that had upheld Ravgen Inc.’s US7332277B2. That patent, filed under application number US10/661165, covers methods for detecting genetic disorders, a technically and commercially significant area spanning prenatal diagnostics and molecular testing. Ravgen, a molecular diagnostics IP company, had previously asserted this patent against multiple laboratory and genomics players.
The Federal Circuit issued its ruling exactly two years after filing, on January 6, 2025, affirming the lower decision in full. The court’s order — ‘AFFIRMED’ — means it found no reversible legal error in the patentability determination below. The basis of termination is recorded as ‘Patent Upheld,’ confirming that US7332277B2 remains valid and enforceable. For LabCorp, this closes the appellate avenue pursued in this case; for Ravgen, it consolidates the patent’s standing after surviving a direct invalidity challenge.
The 731-day duration suggests the appeal involved substantive briefing and potentially oral argument, though the terse affirmance order provides no published reasoning from the public record. What drove the outcome — whether claim construction, prior art scope, or eligibility — is not discernible from the case record alone. Notably, the case was resolved precisely on its two-year anniversary, which may reflect scheduling rather than legal significance. What remains unknown is whether any parallel district court proceedings or IPR petitions touching this patent remain active.
Filing to Patent Upheld in 731 days
731-day appeal — longer than the median Federal Circuit patent appeal (~18 months)
Federal Circuit affirms: what the ruling means for both parties
Affirmance: Federal Circuit finds no reversible error below
When the Federal Circuit affirms, it is confirming that the lower tribunal’s patentability determination was legally sound — that no reversible error of law or clearly erroneous finding of fact warranted overturning the result. The decision does not necessarily endorse every line of reasoning below; it means the outcome stands. For LabCorp as appellant, this exhausts the primary appellate avenue in this case. The affirmance carries precedential weight consistent with its published or non-precedential designation.
Appellate standard of review appliedRavgen’s patent survives — enforceability significantly strengthened
A Federal Circuit affirmance following a direct invalidity challenge is among the most durable outcomes a patent holder can achieve. US7332277B2 now carries the imprimatur of having been tested and upheld at the appellate level, which materially raises the bar for any future challenger. Ravgen can continue licensing or enforcement activity referencing this outcome. The patent’s battle-tested status is a meaningful asset in licensing negotiations with other diagnostic laboratories or genomics companies operating in the genetic disorder detection space.
Patent enforceability reinforcedLabCorp’s invalidity arguments fail — future challenge bar raised
For Laboratory Corporation of America, the affirmance means the invalidity arguments advanced in this appeal did not persuade the Federal Circuit. Further challenge would require a petition to the Supreme Court for certiorari — a narrow and discretionary path — or a new IPR or post-grant proceeding grounded on distinct prior art or grounds not previously raised. The record does not indicate whether LabCorp has parallel proceedings pending. Companies in the clinical diagnostics sector relying on similar detection methods should assess their own exposure independently.
Appellate options exhausted at this levelGenetic disorder detection IP landscape: Ravgen holds a stronger hand
The affirmance strengthens Ravgen’s negotiating position across the clinical and prenatal diagnostics sector. Any laboratory, genomics company, or diagnostic platform that employs methods falling within the scope of US7332277B2 now faces a heightened litigation risk profile. The Federal Circuit’s backing of the patent’s validity makes design-around or invalidity defenses more costly to mount. This outcome is consistent with broader trends of courts upholding molecular diagnostic method patents that clear Section 101 and prior art hurdles at the trial level.
Higher bar for future IPR or challengeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Laboratory Corporation of America Holdings | Company | Clinical laboratory network — appellant challenging validity of US7332277B2Search in Eureka ↗ |
| Defendant | Ravgen, Inc. | Company | Molecular diagnostics IP company — holder of US7332277B2 on genetic disorder detection methodsSearch in Eureka ↗ |
| Plaintiff counsel | Amelia A. DeGory | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Brendan D. Duffy | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Gasper LaRosa | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Gregory A. Castanias | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Jennifer L. Swize | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | John C. Alemanni | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Tina Williams McKeon | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff counsel | Tracy A. Stitt | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff law firm | Jones Day | Law Firm | Representing Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff law firm | Kilpatrick Townsend & Stockton LLP | Law Firm | Representing Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Defendant counsel | Brian Matty | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Defendant counsel | Gabrielle E. Higgins | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Defendant counsel | John M. Desmarais | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Defendant counsel | KerriAnn Limbeek | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Defendant law firm | Desmarais LLP | Law Firm | Representing Ravgen, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a final merits disposition upholding the patentability of US7332277B2. At the Federal Circuit, affirmance under a patentability/invalidity challenge typically reflects application of de novo review on questions of law (such as claim construction or Section 101) and clear error review on factual findings. The terse form of the order suggests either a non-precedential disposition or that the panel found the lower tribunal’s analysis sufficiently sound to require no extended discussion. For Ravgen, this is the strongest possible appellate outcome; for LabCorp, no further Federal Circuit recourse exists in this proceeding.
US7332277B2 — Methods for detection of genetic disorders
US7332277B2, filed under application number US10/661165, protects methods for the detection of genetic disorders — a domain that sits at the intersection of molecular biology, prenatal diagnostics, and clinical laboratory science. The patent covers specific methodological steps enabling detection of genetic abnormalities, which may include techniques applicable to cell-free DNA analysis or similar non-invasive approaches. The application’s filing date contextualises it within an era of rapid development in molecular diagnostics, before next-generation sequencing commoditised some aspects of genetic testing.
Strategically, US7332277B2 represents foundational IP in a sector where diagnostic methods patents carry exceptional commercial value. Ravgen has demonstrated willingness to assert this patent against major laboratory operators, and the Federal Circuit affirmance now makes it one of the more defensible patents in the genetic diagnostics IP landscape. For competitors — including laboratory conglomerates, prenatal testing companies, and genomics platforms — the patent’s upheld status means it cannot be readily designed around without careful claim-by-claim analysis. The affirmance may also signal that Ravgen will pursue further enforcement activity with renewed confidence.
Should you run an FTO analysis against US7332277B2?
Any organisation developing, offering, or operating methods for detecting genetic disorders — including prenatal diagnostics platforms, clinical reference laboratories, liquid biopsy companies, and genomics service providers — should treat US7332277B2 as a live freedom-to-operate concern. The Federal Circuit’s affirmance removes any residual hope that the patent might be invalidated through this channel. If your workflows involve genetic disorder detection methodologies and you have not mapped your processes against the claims of this patent, the risk profile has materially increased following this ruling.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to rapidly map product workflows and diagnostic method steps against the claim language of US7332277B2. Eureka can identify relevant prior art, surface related family members, and flag design-around opportunities — all grounded in the actual prosecution history and post-grant record. Given Ravgen’s enforcement posture and this affirmance, an Eureka-powered FTO review is a proportionate and timely response for any diagnostics company operating in this space.
Run a freedom-to-operate analysis on US7332277B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in genetic diagnostics patent validity
Cases involving Federal Circuit review of genetic disorder detection and molecular diagnostics patent validity, with comparable invalidity challenge postures and appellant profiles.
What this case signals for the genetic diagnostics IP landscape
A Federal Circuit affirmance on a genetic disorder detection patent has real consequences for every laboratory and diagnostics platform in this space.
Battle-tested patents command stronger licensing leverage
US7332277B2 has now survived a Federal Circuit invalidity challenge. In licensing negotiations, Ravgen can credibly represent that the patent withstood one of the most rigorous appellate reviews available. Potential licensees — including diagnostic labs and genomics firms — face a materially weakened invalidity defense relative to an untested patent.
Competitors should audit exposure before the next enforcement wave
Given Ravgen’s prior enforcement history against multiple laboratory players, this affirmance is likely to precede further licensing demands or litigation. Companies running genetic disorder detection workflows should commission a freedom-to-operate analysis against US7332277B2 now, before receiving a demand letter — when options are broader and costs lower.
Laboratory v Ravgen — key questions answered
The Federal Circuit affirmed the lower patentability determination in full, upholding Ravgen’s US7332277B2 covering methods for detection of genetic disorders. The court’s order, issued January 6, 2025, found no reversible error. The basis of termination is recorded as ‘Patent Upheld,’ meaning the patent remains valid and enforceable following LabCorp’s failed invalidity challenge.
US7332277B2, filed under application US10/661165, protects methods for detecting genetic disorders — a technology area spanning prenatal diagnostics, clinical molecular testing, and potentially cell-free DNA analysis. Its commercial significance stems from its broad applicability to laboratory workflows used by major diagnostic operators. Ravgen has historically asserted this patent against multiple laboratory companies, making it a high-value enforcement asset in the clinical diagnostics sector.
Following a Federal Circuit affirmance, LabCorp’s primary remaining option would be a petition for certiorari to the US Supreme Court — a discretionary and narrow path. Alternatively, a new IPR or post-grant proceeding grounded on prior art or grounds not previously raised could theoretically be pursued, though the PTAB applies heightened scrutiny to petitions targeting patents already upheld on appeal. The public record does not indicate any parallel proceedings.
The appeal ran for exactly 731 days, filed January 6, 2023, and decided January 6, 2025. This duration is consistent with — or slightly longer than — a typical Federal Circuit patent appeal, suggesting substantive briefing and possibly oral argument occurred, though the terse affirmance order does not confirm the procedural path taken.
Any laboratory or diagnostics company employing methods for detecting genetic disorders should reassess its FTO position against US7332277B2 following this ruling. The Federal Circuit affirmance removes the invalidity defense as a practical shield in licensing negotiations or litigation. Companies that have not mapped their detection workflows against the patent’s claim scope face elevated infringement risk and should consider a structured FTO analysis before receiving a licensing demand.
PatSnap Eureka searches patents and litigation data to answer instantly.